Canagliflozin approved for type 2 diabetes

被引：2

|

作者：

Traynor, Kate

机构：

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2013年 / 70卷 / 10期

关键词：

D O I：

10.2146/news130035

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

下载

收藏

页码：834 / 834

页数：1

相关论文

共 50 条

[1] Canagliflozin: A Review in Type 2 Diabetes
Deeks, Emma D.
Scheen, Andre J.
DRUGS, 2017, 77 (14) : 1577 - 1592
[2] Canagliflozin (Invokana) for Type 2 Diabetes
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1416): : 1 - 4
[3] Canagliflozin: A Review in Type 2 Diabetes
Emma D. Deeks
André J. Scheen
Drugs, 2017, 77 : 1577 - 1592
[4] CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES
Babu, A.
DRUGS OF TODAY, 2013, 49 (06) : 363 - 376
[5] Canagliflozin and cardiovascular outcomes in Type 2 diabetes
Sarraju, Ashish
Spencer-Bonilla, Gabriela
Rodriguez, Fatima
Mahaffey, Kenneth W.
FUTURE CARDIOLOGY, 2020, 17 (01) : 39 - 48
[6] Safety of Canagliflozin in Patients with Type 2 Diabetes
Mikhail, Nasser
CURRENT DRUG SAFETY, 2014, 9 (02) : 127 - 132
[7] Albiglutide approved for type 2 diabetes
Traynor, Kate
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (11) : 888 - 888
[8] Linagliptin approved for type 2 diabetes
Traynor, Kate
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (12) : 1059 - 1059
[9] Dapagliflozin approved for type 2 diabetes
Traynor, Kate
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (04) : 263 - 263
[10] Renal effects of canagliflozin in patients with Type 2 diabetes
Wong, Yip Fong
Shao, Yanli
Sum, Chee Fang
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S119 - S120

← 1 2 3 4 5 →